Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 3, 2010, Pages 1360-1362

  Chapeland Leclerc, Florence ^a   Hennequin, Christophe ^b   Papon, Nicolas ^c   Noël, Thierry ^d   Girard, Aurélie ^b   Socié, Gérard ^e   Ribaud, Patricia ^e   Lacroix, Claire ^e  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c UNIVERSITÉ DE TOURS   (France)

^d University Victor Segalen   (France)

^e SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CDR1 PROTEIN; CDR2 PROTEIN; FKS2 PROTEIN; FLUCONAZOLE; FLUCYTOSINE; FUNGAL PROTEIN; FUR1 PROTEIN; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ARTICLE; BLOOD CULTURE; CANDIDA GLABRATA; CANDIDEMIA; CANDIDIASIS; CASE REPORT; CENTRAL VENOUS CATHETER; CHILD; DRUG EXPOSURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FANCONI ANEMIA; FEMALE; FUNGAL COLONIZATION; FUNGAL GENE; FUNGUS ISOLATION; GENE OVEREXPRESSION; GENOTYPE; GRAFT FAILURE; GRAFT RECIPIENT; GRANULOCYTE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; SCHOOL CHILD;

EID: 77149169382     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01138-09     Document Type: Article

References (20)

1. Balkis, M. M., S. D. Leidich, P. K. Mukherjee, and M. A. Ghannoum. 2002. Mechanisms of fungal resistance: an overview. Drugs 62:1025-1040.
2. Brisse, S., C. Pannier, A. Angoulvant, T. de Meeus, L. Diancourt, O. Faure, H. Muller, J. Peman, M. A. Viviani, R. Grillot, B. Dujon, C. Fairhead, and C. Hennequin. 2009. Uneven distribution of mating types among genotypes of Candida glabrata isolates from clinical samples. Eukaryot. Cell 8:287-295.
3. Chapeland-Leclerc, F., J. Bouchoux, A. Goumar, C. Chastin, J. Villard, and T. Noël. 2005. Inactivation of the FCY2 gene encoding purine-cytosine permease promotes cross-resistance to flucytosine and fluconazole in Candida lusitaniae. Antimicrob. Agents Chemother. 49:3101-3108.
4. Cleary, J. D., G. Garcia-Effron, S. W. Chapman, and D. S. Perlin. 2008. Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob. Agents Chemother. 52:2263-2265.
5. Daneman, N., A. K. Chan, S. M. Poutanen, R. Rennie, C. Sand, and S. Porter. 2006. The emergence of caspofungin resistance during treatment of recurrent Candida glabrata candidemia. Clin. Microbiol. Infect. 12(Suppl. 4):P1204.
6. Dodgson, K. J., A. R. Dodgson, C. Pujol, S. A. Messer, D. R. Soll, and M. A. Pfaller. 2005. Caspofungin resistant Candida glabrata. Clin. Microbiol. Infect. 11(Suppl. 2):P1158.
7. Garcia-Effron, G., S. Lee, S. Park, J. D. Cleary, and D. S. Perlin. 2009. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-β-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob. Agents Chemother. 53:3690-3699.
8. Hachem, R., H. Hanna, D. Kontoyiannis, Y. Jiang, and I. Raad. 2008. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 112:2493-2499.
9. Katiyar, S., M. Pfaller, and T. Edlind. 2006. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob. Agents Chemother. 50:2892-2894.
10. Krogh-Madsen, M., M. C. Arendrup, L. Heslet, and J. D. Knudsen. 2006. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin. Infect. Dis. 42:938-944.
11. Papon, N., T. Noel, M. Florent, S. Gibot-Leclerc, D. Jean, C. Chastin, J. Villard, and F. Chapeland-Leclerc. 2007. Molecular mechanism of flucytosine resistance in Candida lusitaniae: contribution of the FCY2, FCY1, and FUR1 genes to 5-fluorouracil and fluconazole cross-resistance. Antimicrob. Agents Chemother. 51:369-371.
12. Pappas, P. G., C. A. Kauffman, D. Andes, D. K. Benjamin, Jr., T. F. Calandra, J. E. Edwards, Jr., S. G. Filler, J. F. Fisher, B. J. Kullberg, L. Ostrosky-Zeichner, A. C. Reboli, J. H. Rex, T. J. Walsh, and J. D. Sobel. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
13. Perlin, D. S. 2007. Resistance to echinocandin-class antifungal drugs. Drug Resist. Updat. 10:121-130.
14. Pfaller, M. A., D. J. Diekema, D. L. Gibbs, V. A. Newell, J. F. Meis, I. M. Gould, W. Fu, A. L. Colombo, and E. Rodriguez-Noriega. 2007. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J. Clin. Microbiol. 45:1735-1745.
15. Pfaller, M. A., D. J. Diekema, L. Ostrosky-Zeichner, J. H. Rex, B. D. Alexander, D. Andes, S. D. Brown, V. Chaturvedi, M. A. Ghannoum, C. C. Knapp, D. J. Sheehan, and T. J. Walsh. 2008. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J. Clin. Microbiol. 46:2620-2629.
16. Pfaller, M. A., S. A. Messer, L. Boyken, R. J. Hollis, C. Rice, S. Tendolkar, and D. J. Diekema. 2004. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn. Microbiol. Infect. Dis. 48:201-205.
17. Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, and A. L. Barry. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin. Infect. Dis. 24:235-247.
18. Sanguinetti, M., B. Posteraro, B. Fiori, S. Ranno, R. Torelli, and G. Fadda. 2005. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob. Agents Chemother. 49:668-679.
19. Shin, J. H., M. J. Chae, J. W. Song, S. I. Jung, D. Cho, S. J. Kee, S. H. Kim, M. G. Shin, S. P. Suh, and D. W. Ryang. 2007. Changes in karyotype and azole susceptibility of sequential bloodstream isolates from patients with Candida glabrata candidemia. J. Clin. Microbiol. 45:2385-2391.
20. Thompson, G. R., III, N. P. Wiederhold, A. C. Vallor, N. C. Villareal, J. S. Lewis II, and T. F. Patterson. 2008. Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob. Agents Chemother. 52:3783-3785.